OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product....

A sensor for the lethal bacterial enzyme, botulinum neurotoxin type A (BoNT/A), was developed using self-assembled monolayers (SAMs). SAMs consisting of an immobilized synthetic peptide that mimicked the toxin's in vivo SNAP-25 protein substrate were formed on Au and interfaced with arrayed microfluidic channels. Efforts to optimize SAM composition and assay conditions for greatest reaction eff...

Botulinum neurotoxin type A injection to correct and/or reverse the physical effects of aging process has become one of the most frequently requested cosmetic procedures at an outpatient setting. Careful clinical evaluation together with proper use of the techniques, including pre- and post-procedures recommendations, reconstitution of the products, techniques, and doses, are described in this ...

Botulinum toxin A used to treat headache evokes prominent placebo effects and it is likely that these effects are solely responsible for its apparent effectiveness.

BACKGROUND Localized unilateral hyperhidrosis (LUH) is a rare disorder of unknown origin. We describe a patient with LUH on the forearm, where a fracture was identified as a past injury. OBSERVATIONS We treated the patient with botulinum toxin type A injections, and he was complaint free during the 6 months after treatment. In addition, the initially strong positive results of the iodine star...

Do different formulations of botulinum toxin type A really have different migration characteristics? The dose units of the two main botulinum toxin A products are not equivalent, and there is continuing controversy about the appropriate dose conversion ratio. Cliff et al . 1 report on a study of anhidrotic halos after injections of Dysport and Botox to the forehead at a dose ratio of 3 : 1. The...

UNLABELLED The objective of this study was to evaluate the effects of botulinum toxin type A (BTX-A) on spastic foot in stroke patients in a rehabilitation program. METHOD Hemiparetic stroke patients (n=21) enrolled in a rehabilitation program were divided into two groups. The first group (n=11) received a total of 300 UI BTX-A, and the second group (n=10) received 100 UI BTX-A. All patients ...